in the absence of a submission from the holder of the marketing authorisation:
brentuximab vedotin (Adcetris®) is not recommended for use within NHSScotland.
Indication under review: for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV Hodgkin lymphoma (HL) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice373KB (PDF)
Medicine details
- Medicine name:
- brentuximab (Adcetris)
- SMC ID:
- SMC2925
- Indication:
Adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 May 2026